<VariationArchive VariationID="646155" VariationName="NM_000397.4(CYBB):c.1689del (p.Phe563fs)" VariationType="Deletion" Accession="VCV000646155" Version="7" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="650035" VariationID="646155">
      <GeneList>
        <Gene Symbol="CYBB" FullName="cytochrome b-245 beta chain" GeneID="1536" HGNC_ID="HGNC:2578" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xp21.1-11.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="37780059" stop="37813461" display_start="37780059" display_stop="37813461" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="37639269" stop="37672713" display_start="37639269" display_stop="37672713" Strand="+" />
          </Location>
          <OMIM>300481</OMIM>
          <Haploinsufficiency last_evaluated="2020-05-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CYBB">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-05-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CYBB">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000397.4(CYBB):c.1689del (p.Phe563fs)</Name>
      <CanonicalSPDI>NC_000023.11:37810892:C:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xp11.4</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="37810893" stop="37810893" display_start="37810893" display_stop="37810893" variantLength="1" positionVCF="37810892" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="37670146" stop="37670146" display_start="37670146" display_stop="37670146" variantLength="1" positionVCF="37670145" referenceAlleleVCF="TC" alternateAlleleVCF="T" />
      </Location>
      <ProteinChange>F563fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.37670146del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.37670146del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.37810893del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.37810893del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009065.1" sequenceAccession="NG_009065" sequenceVersion="1" change="g.35877del">
            <Expression>NG_009065.1:g.35877del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000397.4" sequenceAccession="NM_000397" sequenceVersion="4" change="c.1689del" MANESelect="true">
            <Expression>NM_000397.4:c.1689del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000388.2" sequenceAccession="NP_000388" sequenceVersion="2" change="p.Phe563fs">
            <Expression>NP_000388.2:p.Phe563fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_53" sequenceAccession="LRG_53">
            <Expression>LRG_53:g.35877del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000397.3" sequenceAccession="NM_000397" sequenceVersion="3" change="c.1689delC">
            <Expression>NM_000397.3:c.1689delC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1602186299" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000397.4(CYBB):c.1689del (p.Phe563fs) AND Granulomatous disease, chronic, X-linked" Accession="RCV000800384" Version="6">
        <ClassifiedConditionList TraitSetID="3042">
          <ClassifiedCondition DB="MedGen" ID="C1844376">Granulomatous disease, chronic, X-linked</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-14" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10627478</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20724480</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-11">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <DescriptionHistory Dated="2022-05-15">
          <Description>Uncertain significance</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="3042" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1398" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">CYTOCHROME b-NEGATIVE GRANULOMATOUS DISEASE, CHRONIC, X-LINKED</ElementValue>
                <XRef Type="MIM" ID="306400" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Granulomatous disease, chronic, X-linked</ElementValue>
                <XRef ID="MONDO:0010600" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GRANULOMATOUS DISEASE, CHRONIC, X-LINKED, SOMATIC MOSAIC</ElementValue>
                <XRef Type="Allelic variant" ID="300481.0021" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">X-CGD</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CGDX</ElementValue>
                <XRef Type="MIM" ID="306400" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CGD</ElementValue>
                <XRef Type="MIM" ID="306400" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder of phagocytes (neutrophils, monocytes, macrophages, and eosinophils) resulting from impaired killing of bacteria and fungi. CGD is characterized by severe recurrent bacterial and fungal infections and dysregulated inflammatory responses resulting in granuloma formation and other inflammatory disorders such as colitis. Infections typically involve the lung (pneumonia), lymph nodes (lymphadenitis), liver (abscess), bone (osteomyelitis), and skin (abscesses or cellulitis). Granulomas typically involve the genitourinary system (bladder) and gastrointestinal tract (often the pylorus initially, and later the esophagus, jejunum, ileum, cecum, rectum, and perirectal area). Some males with X-linked CGD have McLeod neuroacanthocytosis syndrome as the result of a contiguous gene deletion. While CGD may present anytime from infancy to late adulthood, the vast majority of affected individuals are diagnosed before age five years. Use of antimicrobial prophylaxis and therapy has greatly improved overall survival.</Attribute>
                <XRef ID="NBK99496" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15294" />
                <XRef ID="15294" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">22876374</ID>
                <ID Source="BookShelf">NBK99496</ID>
              </Citation>
              <XRef ID="379" DB="Orphanet" />
              <XRef ID="C1844376" DB="MedGen" />
              <XRef ID="MONDO:0010600" DB="MONDO" />
              <XRef Type="MIM" ID="306400" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1834015" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="4537973|MedGen:C1844376" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000940096" DateUpdated="2024-02-14" DateCreated="2019-08-14" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10627478</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20724480</ID>
          </Citation>
          <Comment>This variant has not been reported in the literature in individuals affected with CYBB-related conditions. This sequence change results in a frameshift in the CYBB gene (p.Phe563Leufs*14). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 8 amino acid(s) of the CYBB protein and extend the protein by 5 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). ClinVar contains an entry for this variant (Variation ID: 646155). This variant disrupts a region of the CYBB protein in which other variant(s) (p.Glu568Lys ) have been determined to be pathogenic (PMID: 10627478, 20724480; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CYBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.37670146del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1844376" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1834015" TraitType="Disease" MappingType="XRef" MappingValue="C1844376" MappingRef="MedGen">
        <MedGen CUI="C1844376" Name="Granulomatous disease, chronic, X-linked" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

